Evidence map›Paper›PMID 26908120›Full record

Trial reportDer Urologe. Ausg. A2016

[PREFERE - Study on the rise].

Carsten-H Ohlmann, Michael Stöckle, Peter Albers, Heinz Schmidberger, Martin Härter, Glen Kristiansen, Peter Martus, Stefan Wellek, Roswitha Bussar-Maatz, Thomas Wiegel

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Der Urologe. Ausg. A, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Carsten-H OhlmannKlinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Kirrbergerstr., 66421, Homburg/Saar, Deutschland. carsten.ohlmann@uks.eu.
Michael StöckleKlinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Kirrbergerstr., 66421, Homburg/Saar, Deutschland.
Peter AlbersKlinik für Urologie, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland.
Heinz SchmidbergerKlinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Mainz, Mainz, Deutschland.
Martin HärterInstitut und Poliklinik für medizinische Psychologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
Glen KristiansenInstitut für Pathologie, Universitätsklinikum Bonn, Bonn, Deutschland.
Peter MartusInstitut für Klinische Epidemiologie und Angewandte Biometrie, Universität Tübingen, Tübingen, Deutschland.
Stefan WellekInstitut für Medizinische Biometrie, Epidemiologie und Informatik, Universität Mainz, Mainz, Deutschland.
Roswitha Bussar-MaatzKlinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Kirrbergerstr., 66421, Homburg/Saar, Deutschland.
Thomas WiegelKlinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Ulm, Ulm, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The PREFERE study, which compares the treatment options for prostate cancer with low and early intermediate risk, has recorded a noticeable upswing in recruitment since mid-2015. Responsible for this are the revised inclusion criteria and the wide support for this study in Germany. The inclusion criteria opened the study to the use of imaging techniques (MRI, C‑Trus / Anna) and the inclusion of all Gleason 3 + 3 = 6 cancers, regardless of tumor extent. In addition, patients can now be included who, for example due to the size of the prostate or existing obstructive micturition disorders, had a contraindication to percutaneous radiotherapy or brachytherapy - these can now be randomized between active surveillance and radical prostatectomy. With the increased recruitment numbers, it seems realistic that the required milestones in recruiting will be achieved.

Indexed as

ComorbidityDiagnostic ImagingEvidence-Based MedicineGermanyHumansInternationalityMalePatient SelectionPostoperative ComplicationsProstatectomyProstatic NeoplasmsRadiation InjuriesRadiotherapySurvival RateTreatment OutcomeBrachtherapyImage-guided biopsyPatient selectionProstatectomyProstatic neoplasmsRadiotherapy

Identifiers

PMID26908120

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.